Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Cash from Financing Activities (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Cash from Financing Activities for 16 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 59.14% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $428.2 million through Dec 2025, up 340.83% year-over-year, with the annual reading at $428.2 million for FY2025, 340.83% up from the prior year.
  • Cash from Financing Activities hit $8.3 million in Q4 2025 for Ligand Pharmaceuticals, down from $409.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $409.6 million in Q3 2025 to a low of -$170.4 million in Q1 2022.
  • Historically, Cash from Financing Activities has averaged $2.6 million across 5 years, with a median of $1.4 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 998000.0% in 2021 and later soared 1671.87% in 2024.
  • Year by year, Cash from Financing Activities stood at $4.2 million in 2021, then plummeted by 227.23% to -$5.3 million in 2022, then skyrocketed by 200.32% to $5.3 million in 2023, then soared by 283.59% to $20.4 million in 2024, then plummeted by 59.14% to $8.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for LGNDZ at $8.3 million in Q4 2025, $409.6 million in Q3 2025, and $15.0 million in Q2 2025.